PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

[1]  Neha S. Gandhi,et al.  Heparin/heparan sulphate-based drugs. , 2010, Drug discovery today.

[2]  R. Sanderson,et al.  Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis , 2010, The FEBS journal.

[3]  David M. Shackleford,et al.  Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. , 2010, Journal of medicinal chemistry.

[4]  T. Gonda,et al.  The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy , 2010, Investigational New Drugs.

[5]  Q. Tong,et al.  Expression and clinical significance of heparanase in neuroblastoma , 2009, World journal of pediatrics : WJP.

[6]  K. Hunter,et al.  Preclinical Drug Development Must Consider the Impact on Metastasis , 2009, Clinical Cancer Research.

[7]  L. Jeng,et al.  Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. , 2009, Journal of hepatology.

[8]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[9]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[10]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[11]  Y. Okada,et al.  Expression of Heparanase in Renal Cell Carcinomas: Implications for Tumor Invasion and Prognosis , 2008, Clinical Cancer Research.

[12]  Zhen-bo Feng,et al.  Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. , 2008, Oncology research.

[13]  M. Nakajima,et al.  Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. , 2008, Oncology reports.

[14]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[15]  E. Mckenzie,et al.  Heparanase: a target for drug discovery in cancer and inflammation , 2007, British journal of pharmacology.

[16]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[17]  D. Gustafson,et al.  A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors , 2006, Clinical Cancer Research.

[18]  K. Norrby.  Low‐molecular‐weight heparins and angiogenesis , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  I. Vlodavsky,et al.  Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. , 2006, Cancer research.

[20]  Vito Ferro,et al.  Heparanase as a Target for Anticancer Therapeutics: New Developments and Future Prospects , 2006 .

[21]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[22]  Vito Ferro,et al.  Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). , 2005, Journal of medicinal chemistry.

[23]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[24]  J. Kendrew,et al.  Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor , 2005, Molecular Cancer Therapeutics.

[25]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[26]  R. Gray,et al.  Evaluating Antiangiogenesis Agents in the Clinic , 2004, Clinical Cancer Research.

[27]  D. Ron,et al.  Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor , 1996, Cancer and Metastasis Reviews.

[28]  J. Reiland,et al.  INHIBITION OF HEPARANASE ACTIVITY AND HEPARANASE-INDUCED ANGIOGENESIS BY SURAMIN ANALOGUES , 2003 .

[29]  R. Abramovitch,et al.  Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Bucana,et al.  Quantitative and qualitative in vivo angiogenesis assay. , 2002, International journal of oncology.

[31]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[32]  T. Peretz,et al.  Inhibition of tumor metastasis by heparanase inhibiting species of heparin. , 1994, Invasion & metastasis.

[33]  T. Irimura,et al.  Heparanases and tumor metastasis , 1988, Journal of cellular biochemistry.